Develops eye treatments for retinal diseases.
Jun 2026Revenue $52.1M/yrExpenses $366M/yr
No trendCash runway ≈ 2.3 years from Jun 2026
Figures by year
When will Ocular Therapeutix be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $52.1M and expenses $366M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $52.0M | $322M | −$270M |
| Dec 2024 | $63.7M | $236M | −$172M |
| Dec 2023 | $58.4M | $141M | −$82.4M |
| Dec 2022 | $51.5M | $130M | −$78.7M |
| Dec 2021 | $43.5M | $122M | −$78.0M |
| Dec 2020 | $17.4M | $80.3M | −$62.8M |
| Dec 2019 | $4.23M | $90.0M | −$85.8M |
| Dec 2018 | $1.99M | $61.1M | −$59.1M |
| Dec 2017 | $1.92M | $63.8M | −$61.9M |
| Dec 2016 | $1.89M | $45.2M | −$43.3M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.